Glycinova-GP 2mg/500mg/1.5mg Tablet ER
Marketer
Ikon Remedies Pvt Ltd
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Pioglitazone (1.5mg)
Overview Glycinova-GP 2mg/500mg/1.5mg Tablet ER
DiaBeta-XR 2mg/500mg/1.5mg Extended-Release Tablets combine medications to manage blood glucose. This regimen, used alongside diet and exercise, improves glycemic control in adults with type 2 diabetes. It enhances insulin effectiveness, reducing blood sugar. Follow your physician's prescribed dosage and frequency for DiaBeta-XR. Take it with food to prevent stomach discomfort. If a dose is missed, take it promptly; however, if nearing the next dose, omit the missed one and resume your usual schedule. Never double the dose. Overdosing can cause hypoglycemia (low blood sugar). Concurrent use with other diabetes medications, alcohol, or skipped meals may increase hypoglycemia risk; regular blood sugar monitoring is crucial. Common side effects may include nausea, diarrhea, abdominal pain, headache, bone fractures, and respiratory infections. Inform your doctor of any kidney, liver, or heart issues before starting this medication. Pregnant or lactating individuals should consult their physician. Kidney function tests will be performed before treatment commences. Limit alcohol consumption, as it can heighten the risk of adverse effects.
Uses of Glycinova-GP 2mg/500mg/1.5mg Tablet ER
Managing type 2 diabetes
Major Benefits of Glycinova-GP 2mg/500mg/1.5mg Tablet ER:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Glycinova-GP 2mg/500mg/1.5mg Extended-Release tablet whole; avoid chewing, crushing, or fracturing it. Consume this medication with food.
Common Side effects of Glycinova-GP 2mg/500mg/1.5mg Tablet ER:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Glycinova-GP 2mg/500mg/1.5mg Tablet ER:
Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. Ingest the Glycinova-GP 2mg/500mg/1.5mg Extended-Release tablet whole; avoid chewing, crushing, or fracturing it. Consume this medication with food.
How Glycinova-GP 2mg/500mg/1.5mg Tablet ER works:
Glycinova-GP Extended-Release tablets (2mg/500mg/1.5mg) contain glimepiride, metformin, and pioglitazone—three antidiabetic agents with distinct actions. This triple combination improves blood glucose management when monotherapy or dual therapy proves insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood sugar levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose uptake, and enhancing insulin responsiveness. Pioglitazone, a thiazolidinedione, further boosts insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glycinova-GP 2mg/500mg/1.5mg Extended-Release tablets with alcohol is contraindicated.
PregnancyCONSULT YOUR DOCTOR
Extended-release Glycinova-GP tablets (2mg/500mg/1.5mg) may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against potential dangers prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Glycinova-GP tablets (2mg/500mg/1.5mg) are likely not safe for breastfeeding mothers. Available data from humans indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyCAUTION
Exercise caution when prescribing Glycinova-GP 2mg/500mg/1.5mg ER tablets to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Glycinova-GP 2mg/500mg/1.5mg ER tablets are contraindicated in patients exhibiting severe kidney disease. Close monitoring of kidney function parameters is recommended during treatment.
LiverCAUTION
Patients with hepatic impairment should use Glycinova-GP 2mg/500mg/1.5mg Extended-Release tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. Glycinova-GP 2mg/500mg/1.5mg Extended-Release tablets are contraindicated in individuals with severe liver disease.
What if you forget to take Glycinova-GP 2mg/500mg/1.5mg Tablet ER :
Should you forget a Glycinova-GP 2mg/500mg/1.5mg Extended-Release tablet, ingest it immediately upon recollection. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glycinova-GP 2mg/500mg/1.5mg Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently